Subscribe
fcm82 / Shutterstock.com
29 May 2025NewsAmericasMarisa Woutersen

Weight-loss clinic hits back at Novo Nordisk’s Ozempic TM allegations

Novo Nordisk faces resistance from Connecticut clinic in Ozempic and Wegovy dispute | LIVation admits to referencing Novo Nordisk products in past marketing but it has since been removed | Clinic claims its compounded semaglutide use was lawful and clear to patients.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
15 October 2024   Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Americas
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
11 September 2024   Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.
Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
15 October 2024   Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Americas
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
11 September 2024   Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.
Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.

More on this story

Americas
Novo Nordisk targets Canada’s largest generics maker over diabetes drug
15 October 2024   Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.
Americas
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
11 September 2024   Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.
Big Pharma
Novo Nordisk’s uphill battle in the counterfeit weight loss craze
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.

More features

Eisai and Merck shield blockbuster cancer drug from generic challenge
Fed Circ refuses to stay Novartis feud with MSN over Entresto
Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute